Shareholders to Vote on Repricing 9.5M Underwater Options and Adding 7.7M Shares to Equity Plan
Summary
Coherus Oncology is seeking shareholder approval for two significant equity-related proposals: repricing 9.54 million underwater stock options to current market levels and adding 7.7 million shares to its equity incentive plan, both of which are highly dilutive but aimed at employee retention.
Key Events
-
Annual Meeting Scheduled
The 2026 Annual Meeting of Stockholders will be held virtually on May 27, 2026, to vote on several key proposals.
-
Option Repricing Proposal
Shareholders will vote on a proposal to reduce the exercise price of 9,540,140 outstanding stock options, currently with exercise prices between $5.44 and $30.98, to the closing trading price on the date of the Annual Meeting. This aims to restore incentive and retention for employees holding underwater options.
-
Equity Plan Share Increase Proposal
A proposal seeks to increase the number of shares reserved for issuance under the 2014 Equity Incentive Award Plan by 7,700,000 shares. This represents approximately 4.99% potential dilution based on current outstanding shares.
-
Board Size Reduction
The Board of Directors determined to reduce its size from nine members to eight, effective immediately prior to the election of directors at the 2026 Annual Meeting. Director Georgia Erbez is not standing for re-election.
Analysis
Coherus Oncology is seeking shareholder approval for two highly dilutive equity-related proposals at its upcoming annual meeting. The proposed repricing of 9.54 million underwater stock options, with original exercise prices significantly above the current stock price, aims to restore employee incentives and retention. This move, while potentially boosting morale, represents a substantial transfer of value from shareholders. Concurrently, the request to add 7.7 million shares to the equity incentive plan, representing nearly 5% potential dilution, further emphasizes the company's reliance on equity to attract and retain talent in a challenging market. These proposals follow a strategic pivot to oncology and come after a year where the company's stock price has remained low, making existing options less effective. The outcome of these votes will significantly impact future share structure and employee compensation.
At the time of this filing, CHRS was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $296.8M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.